First-line treatment for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs for people with advanced liver cancer who have not had prior treatment. It compares the study drug QL1706 plus standard treatments to see if it can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and at most 80 years old.
- You have been diagnosed with liver cancer (hepatocellular carcinoma).
- Your cancer is at an advanced stage (BCLC stage C) or stage B that cannot be treated with surgery or local therapy.
- You have not received any systemic treatment for your liver cancer before.
- Your liver function is good enough (Child-Pugh score 7 or less) and you have not had hepatic encephalopathy.
- You do not have other cancers (except certain types) or serious fluid buildup in the belly or chest that is not controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (ZG005 plus bevacizumab) against a standard one (sintilimab plus bevacizumab) as the first treatment for advanced liver cancer that cannot be removed by surgery. The goal is to see if the new combination works better at shrinking tumors or delaying progression.
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
This Phase 2 trial tests three medicines together (durvalumab, tremelimumab, and bevacizumab) to treat non-surgical (non-resectable) liver cancer. It may help shrink tumors and slow disease progression by boosting the immune system and blocking tumor blood supply.
This trial tests a combination of three drugs—valemetostat, atezolizumab, and bevacizumab—for people with advanced liver cancer (HCC) who have not had systemic treatment before. The goal is to see if this combination can shrink tumors or slow disease progression.
This trial tests a new drug called SH006 combined with another treatment against a standard drug (regorafenib) for advanced liver cancer. It is for people whose cancer has stopped responding to immunotherapy, and the goal is to see if it helps them live longer or shrinks the tumor.
This trial tests a new combination of two immunotherapy drugs (IBI310 and sintilimab) as a first treatment for advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and works better than current options.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.